Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (312)	12/23/2002 4:43:14 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 631

Now, DNA have some chance to reach market before BGEN (50:50). Press Release Source: Genentech Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva -- Efalizumab -- for the Treatment of Moderate-to-Severe Plaque Psoriasis Monday December 23, 4:30 pm ET SOUTH SAN FRANCISCO, Calif. & BERKELEY, Calif.--(BUSINESS WIRE)--Dec. 23, 2002--Genentech, Inc. (NYSE: DNA - News) and XOMA Ltd. (Nasdaq: XOMA - News) today announced they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Raptiva(TM) (Efalizumab), a recombinant humanized monoclonal antibody under evaluation for the treatment of moderate-to-severe plaque psoriasis.